Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570063 · ClinicalTrials.gov registry record · Phase 2
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00570063 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 35 participants.
The verdict
NCT00570063, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of an investigational compound PF-02545920 for the treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing symptoms associated with schizophrenia.
Interventions
- DRUG Placebo
- DRUG PF-02545920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570063
The ClinicalTrials.gov registry entry for NCT00570063 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00570063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570063 about?
NCT00570063 is a clinical study titled "Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo". To assess the efficacy and safety of an investigational compound PF-02545920 for the treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing symptoms associated with schizophrenia.
What is the current status of trial NCT00570063?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2007-11. Estimated completion is 2008-02-18.
What interventions are being tested in trial NCT00570063?
The interventions under investigation include: Placebo (DRUG), PF-02545920 (DRUG).
Who is sponsoring clinical trial NCT00570063?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.